Navigation Links
New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn's Patients With Fistulizing Disease
Date:12/5/2008

Improved outcomes for fistula closures observed in PRECiSE 2 trial under maintenance therapy with stable dosing of CIMZIA(R) every four weeks

HOLLYWOOD, Fla., Dec. 5 /PRNewswire-FirstCall/ -- Data presented this week by UCB at Advances in Inflammatory Bowel Diseases 2008, the Crohn's & Colitis Foundation's Clinical & Research Conference, demonstrated more than half (53.6%) of those moderate to severe Crohn's disease patients who had open fistulas at baseline had closure of fistulas by Week 26 following short-term induction therapy with CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNFa (Tumor Necrosis Factor alpha). Additionally, the data showed that fistulas in most of these patients treated continuously with CIMZIA(R) stayed closed with a majority of patients achieving clinical remission.

CIMZIA(R) is indicated for reducing the signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severe active disease who have had an inadequate response to conventional therapy.

Fistulas are abnormal tunnels or tracts that develop in response to inflammation and ulceration associated with CD. Fistulas may originate from the intestinal tract or rectum and connect to the bladder, vagina, skin or other intestinal areas. If left untreated, fistulas may cause a decrease in absorption of nutrients from food, abnormal drainage of bowel contents into other organs, or a life-threatening infection or abscess.

These results focus on a subpopulation of adult, moderate to severe Crohn's disease patients with fistulizing disease who took part in PRECiSE 2, the Phase III maintenance study of CIMZIA(R). In PRECiSE 2, patients received an open-label induction with subcutaneous CIMZIA(R) 400 mg at Weeks 0, 2 and 4. Those who responded to treatment (reduction of less than or equal to 100 points from baseline on the Crohn's Disease Activity
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
2. 454 Sequencing(TM): Science Paper Suggests That Structural Variation Plays an Important Role in Genetic Variation
3. Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
4. New MedPredict Report Suggests Market for Alcoholism Therapies is Underestimated
5. Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimers Disease
6. Chest Physicians Now Suggest Early Intervention for Certain Blood Clots in DVT
7. Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Arent Risk Takers
8. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
9. Data Presented at Cancer Molecular Markers Meeting Suggests Clinical Benefit for Integrating New Molecular Tests
10. CorMatrix Announces Pre-Clinical Data Suggesting Next Generation ECM Technology(TM) Can Improve Cardiac Function
11. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that ... Cancer Care , a national support services organization for people ... educational programs for people facing lung and ovarian cancers.  The ... their families become aware of options available to help treat ...
... graphite particles 1000 times smaller than the width of a ... boost the efficiencyand profitabilityof solar power plants. Photovoltaic (PV) ... but they,re not necessarily the best solar power solution. "The ... only a fraction of the sunlight that hits them, and ...
... PARIS, April 5, 2011 Cellectis (Alternext: ALCLS), the genome ... signed an agreement with the Caisse des Depots (a French ... in two steps, reserved in equal parts to Cellectis and ... later than January 31, 2012, and is subject to the ...
Cached Biology Technology:Morphotek®, Inc. Receives Beacon Award From CancerCare 2Morphotek®, Inc. Receives Beacon Award From CancerCare 3Nanoparticles improve solar collection efficiency 2Cellectis and Caisse des Depots Sign Agreement on a Project for the Industrial Development of iPS Cells 2Cellectis and Caisse des Depots Sign Agreement on a Project for the Industrial Development of iPS Cells 3
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... GAINESVILLE, Fla. New University of Florida research puts to ... the last glacial period. It turns out it ended up ... The findings have implications for modern-day global warming, said ... of the paper, which is published in this week,s journal ...
... team of researchers based at the Institute of Vertebrate ... professor at Washington University in St. Louis, has discovered ... anthropologists perceptions of the emergence of modern humans in ... published Oct. 25 in the online early edition of ...
... HOUSTON, Oct. 25, 2010 Some unexpected effects ... and reverse blindness have been uncovered by a University ... Donald A. Fox, a professor of vision sciences ... findings in a paper titled "Low-Level Gestational Lead Exposure ...
Cached Biology News:UF research gives clues about carbon dioxide patterns at end of Ice Age 2UF research gives clues about carbon dioxide patterns at end of Ice Age 3Unexpected findings of lead exposure may lead to treating blindness 2Unexpected findings of lead exposure may lead to treating blindness 3